One main reason might be the administration of multiple ALK inhibitor and chemotherapy lines, because more different types and lines of treatment have been linked to longer survival in both ALK+NSCLC and LCNEC (Elsayed et al. 2021; Fisch et al. 2021). The gene discussed is ALK; the disease is non-small cell lung carcinoma.